ERBB2 and non-small cell lung carcinoma: High throughput sequencing of major tumors has improved the understanding of molecular mechanisms of tumor transformation and progression [22] and led to the development of several oncogenes-targeting therapies, including the c-KIT inhibitor Imatinib, the anti-HER2 agent Trastuzumab and the ALK inhibitor Crizotinib for the treatment of chronic myeloid leukemia (CML), non-small cell lung cancer (NSCLC) and breast cancer [23].